• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the Editor Regarding 'Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)'.

作者信息

Kristen Arnt V, Tschöpe Carsten, Schwarting Stephanie, Siepen Fabian Aus dem

机构信息

Department of Cardiology, University of Heidelberg, Heidelberg, Germany.

Kardiovaskuläres Zentrum Darmstadt, Dieburger Str. 31C, 64287, Darmstadt, Germany.

出版信息

Cardiol Ther. 2024 Dec;13(4):811-814. doi: 10.1007/s40119-024-00382-5. Epub 2024 Oct 23.

DOI:10.1007/s40119-024-00382-5
PMID:39441481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11607198/
Abstract
摘要

相似文献

1
Letter to the Editor Regarding 'Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)'.致编辑的信：关于“61毫克氯苯唑酸的患者特征与持续性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析”
Cardiol Ther. 2024 Dec;13(4):811-814. doi: 10.1007/s40119-024-00382-5. Epub 2024 Oct 23.
2
A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)".对《致编辑的信：关于“61毫克氯苯唑酸的患者特征与持续性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析”》的回应
Cardiol Ther. 2024 Dec;13(4):815-817. doi: 10.1007/s40119-024-00383-4. Epub 2024 Oct 23.
3
Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).61毫克氯苯唑酸的患者特征与用药依从性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析
Cardiol Ther. 2024 Jun;13(2):369-378. doi: 10.1007/s40119-024-00365-6. Epub 2024 Apr 13.
4
German longitudinal prescription database (LRx): Description of characteristics, use in pharmacoepidemiological research, and limitations
.德国纵向处方数据库（LRx）：特征描述、在药物流行病学研究中的应用及局限性
Int J Clin Pharmacol Ther. 2024 Jan;62(1):20-28. doi: 10.5414/CP204485.
5
Influenza vaccination coverage in the 2004/05, 2005/06, and 2006/07 seasons: a secondary data analysis based on billing data of the German associations of statutory health insurance physicians.2004/05、2005/06 和 2006/07 流感季节的疫苗接种覆盖率：基于德国法定医疗保险医师协会计费数据的二次数据分析。
Dtsch Arztebl Int. 2010 Dec;107(48):845-50. doi: 10.3238/arztebl.2010.0845. Epub 2010 Dec 3.
6
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort.经转甲状腺素蛋白淀粉样变心肌病诊断和/或接受他司美坦治疗的医疗保险患者的基线特征和二级药物依从性：医疗保险队列的回顾性分析。
J Manag Care Spec Pharm. 2022 Jul;28(7):766-777. doi: 10.18553/jmcp.2022.28.7.766.
7
[Compilation of Second Opinion Programs in the German Statutory Health Insurance].[德国法定医疗保险中第二诊疗意见项目汇编]
Gesundheitswesen. 2018 Oct;80(10):859-863. doi: 10.1055/s-0043-105576. Epub 2017 May 15.
8
[The German Statutory Accident Insurance: A successful example of a value-based healthcare structure].[德国法定事故保险：基于价值的医疗保健结构的成功范例]
Z Evid Fortbild Qual Gesundhwes. 2018 Feb;130:13-20. doi: 10.1016/j.zefq.2017.07.009. Epub 2017 Sep 1.
9
Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany.在德国开展的一项全国性纵向队列研究：维立西呱治疗患者的真实世界特征和使用模式。
Eur J Clin Pharmacol. 2024 Jun;80(6):931-940. doi: 10.1007/s00228-024-03654-0. Epub 2024 Mar 12.
10
Analysis of second opinion programs provided by German statutory and private health insurance - a survey of statutory and private health insurers.德国法定和私人健康保险提供的第二诊疗意见计划分析——对法定和私人健康保险公司的调查。
BMC Health Serv Res. 2021 Mar 9;21(1):209. doi: 10.1186/s12913-021-06207-8.

引用本文的文献

1
A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)".对《致编辑的信：关于“61毫克氯苯唑酸的患者特征与持续性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析”》的回应
Cardiol Ther. 2024 Dec;13(4):815-817. doi: 10.1007/s40119-024-00383-4. Epub 2024 Oct 23.

本文引用的文献

1
Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis.标准心力衰竭药物治疗对心脏转甲状腺素蛋白淀粉样变患者的预后价值
J Clin Med. 2024 Apr 12;13(8):2257. doi: 10.3390/jcm13082257.
2
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio.患有心脏淀粉样变性的β受体阻滞剂治疗患者：谨慎前行。
Int J Cardiol. 2024 Jul 15;407:132039. doi: 10.1016/j.ijcard.2024.132039. Epub 2024 Apr 12.
3
Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).61毫克氯苯唑酸的患者特征与用药依从性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析
Cardiol Ther. 2024 Jun;13(2):369-378. doi: 10.1007/s40119-024-00365-6. Epub 2024 Apr 13.
4
Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis.β受体阻滞剂在心肌淀粉样变患者中的耐受性和有效性：系统评价和荟萃分析。
Int J Cardiol. 2024 May 1;402:131813. doi: 10.1016/j.ijcard.2024.131813. Epub 2024 Jan 24.
5
Conventional heart failure therapy in cardiac ATTR amyloidosis.心脏肌球蛋白重链ATTR 淀粉样变的常规心力衰竭治疗。
Eur Heart J. 2023 Aug 14;44(31):2893-2907. doi: 10.1093/eurheartj/ehad347.
6
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗：欧洲心脏病学会心肌与心包疾病工作组的立场声明
Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
7
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.特发性甲状腺素运载蛋白淀粉样变心肌病患者的塔法米迪治疗。
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
8
Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?心脏转甲状腺素蛋白淀粉样变的标准心力衰竭药物：有益还是有害？
Amyloid. 2017 Mar;24(sup1):132-133. doi: 10.1080/13506129.2016.1272453.